Monopar Therapeutics (NASDAQ:MNPR) Director Sells $351,181.34 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Raymond Anderson sold 3,142 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total value of $351,181.34. Following the transaction, the director owned 23,751 shares of the company’s stock, valued at approximately $2,654,649.27. This trade represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Price Performance

MNPR opened at $111.89 on Friday. Monopar Therapeutics Inc. has a 12-month low of $32.77 and a 12-month high of $124.82. The stock has a market capitalization of $750.78 million, a PE ratio of -51.56 and a beta of 1.47. The firm’s fifty day moving average price is $106.44 and its 200 day moving average price is $75.00.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.02. On average, equities research analysts forecast that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in MNPR. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics during the 3rd quarter valued at approximately $28,000. BNP Paribas Financial Markets increased its position in Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new stake in Monopar Therapeutics in the fourth quarter worth $65,000. Caitong International Asset Management Co. Ltd bought a new stake in Monopar Therapeutics in the fourth quarter valued at $86,000. Finally, JPMorgan Chase & Co. lifted its stake in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on MNPR shares. Piper Sandler set a $105.00 target price on Monopar Therapeutics in a research report on Tuesday, June 2nd. HC Wainwright raised their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Zacks Research downgraded shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, BTIG Research increased their target price on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Monopar Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $118.67.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.